[
  {
    "ts": null,
    "headline": "Building A $1,000,000 Dividend Portfolio: A Strategy For Growth, Income And Risk Management",
    "summary": "A high net worth dividend portfolio should prioritize capital preservation. Read more about an investment approach that offers diversification and helps generate extra income.",
    "url": "https://finnhub.io/api/news?id=d1598733946b0265a4aa2bc5b8b544b58252b4c9cfb2240b4a67f36ebb3c2056",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740679200,
      "headline": "Building A $1,000,000 Dividend Portfolio: A Strategy For Growth, Income And Risk Management",
      "id": 132901465,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1248114016/image_1248114016.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "A high net worth dividend portfolio should prioritize capital preservation. Read more about an investment approach that offers diversification and helps generate extra income.",
      "url": "https://finnhub.io/api/news?id=d1598733946b0265a4aa2bc5b8b544b58252b4c9cfb2240b4a67f36ebb3c2056"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=2fcd2b26e56d7999b546c19d2f923abf09a108ff50753d993eafd0542404825f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740664819,
      "headline": "Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 132902091,
      "image": "https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=2fcd2b26e56d7999b546c19d2f923abf09a108ff50753d993eafd0542404825f"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ): One of the Best Vaccine Stocks to Buy According to Hedge Funds",
    "summary": "We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other best vaccine stocks to buy now. What Will Trump’s Tariffs Mean for the Pharma Industry? On February 24, […]",
    "url": "https://finnhub.io/api/news?id=f4442afa8e5c1c3d266ca28be895de77ea4463f2bf14af9b67124dbf654195b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740663513,
      "headline": "Johnson & Johnson (JNJ): One of the Best Vaccine Stocks to Buy According to Hedge Funds",
      "id": 132902093,
      "image": "https://s.yimg.com/ny/api/res/1.2/DBFyZ0OZ_JyFkP8R8eQoiQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other best vaccine stocks to buy now. What Will Trump’s Tariffs Mean for the Pharma Industry? On February 24, […]",
      "url": "https://finnhub.io/api/news?id=f4442afa8e5c1c3d266ca28be895de77ea4463f2bf14af9b67124dbf654195b4"
    }
  },
  {
    "ts": null,
    "headline": "Atai: Following The Path That Spravato Laid And Moving Beyond It",
    "summary": "Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.",
    "url": "https://finnhub.io/api/news?id=5a8728afcd9574d751d0be982edbad9b1d9817e00d9e76bd1f8d6dee45b7ea03",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740660314,
      "headline": "Atai: Following The Path That Spravato Laid And Moving Beyond It",
      "id": 132900558,
      "image": "https://static.seekingalpha.com/uploads/2018/11/21/podcast_series_header.png",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.",
      "url": "https://finnhub.io/api/news?id=5a8728afcd9574d751d0be982edbad9b1d9817e00d9e76bd1f8d6dee45b7ea03"
    }
  },
  {
    "ts": null,
    "headline": "Why Novartis Remains A 'Buy' After Beating Expectations Again",
    "summary": "Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read why I maintain my Buy rating on NVS.",
    "url": "https://finnhub.io/api/news?id=b49f962f627f1665d614d75198e399ec2db6f521a9c90fdc497f9d42746bdc43",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740650974,
      "headline": "Why Novartis Remains A 'Buy' After Beating Expectations Again",
      "id": 132900099,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1795327693/image_1795327693.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read why I maintain my Buy rating on NVS.",
      "url": "https://finnhub.io/api/news?id=b49f962f627f1665d614d75198e399ec2db6f521a9c90fdc497f9d42746bdc43"
    }
  }
]